March
VPAG 2026
Expert insights on pricing, access and policy changes shaping the year ahead
Join our expert panel as they review the latest updates to the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) and what they mean for Life Sciences in 2026.
April
Value Frameworks as a Predictor of HTA Success
How value frameworks shape clinical benefit assessment, uncertainty and reimbursement outcomes
How do value frameworks influence HTA decisions? In this 60-minute masterclass, LSE Professor Panos Kanavos explores how clinical benefit assessment tools, uncertainty management and decision modifiers shape reimbursement outcomes across global markets.